Importantly, especially C9-HRE carriers and FTD-MND patients, who characteristically display TDP-43 neuropathology, showed lower serum TDP-43 levels as compared to the HC group, whereas no difference was observed between the HC group and FTD-tau patients, implicating that these findings are specific and relevant. This evidence concerns the gene TARDBP and mild neurocognitive disorder.